Connect Biopharma Holdings Limited (NASDAQ:CNTB) announced that data from Stage 1 of the ongoing pivotal CBP-201 China trial in moderate-to-severe atopic dermatitis (AD) showed rapid relief from symptoms, as early as week one in some cases, and no efficacy plateau at Week 16. The study met primary and secondary endpoints with mostly mild-to-moderate adverse effects reported. The data were presented as a late-breaking oral presentation today at the American Academy of Dermatology Annual Meeting, taking place in New Orleans, March 17-21.
Chesapeake Energy’s Debt Overview
Over the past three months, shares of Chesapeake Energy Inc. (NASDAQ:CHK) decreased by 7.35%. When understanding a companies price change over a time period like 3 months, it could be helpful to look at its financials.
